9:00 am Chair’s Opening Remarks

  • Kipp Weiskopf Clinical Fellow, Hematology & Oncology, Dana-Farber Cancer Institute

9:30 am Panel Discussion: Defining Metrics of Success with Macrophage-directed Therapeutics

Synopsis

Key questions to address:
• What does success look like when manipulating macrophage phenotypes?
• Is success defined through restructuring the tumor microenvironment or activating t cell infiltration to the tumor site?
• What will be the most relevant strategy clinically addressing macrophages?
• Define the most important parameters around this modality that will reflect translational viability in humans

Characterize Macrophage Cell Types with Novel Biomarkers to Understand their Contribution to Tumor Progression

10:30 am Exploiting Macrophages as a Target for Therapy in Breast Cancer (BC)

Synopsis

• Analyze the macrophage profile in BC subpopulations
• Review translational approaches to incorporate macrophage targeting in BC treatment
• Outline molecular imaging strategies to guide these approaches

11:00 am Morning Refreshments & Networking

Genetically Engineered Macrophages to Target Solid Tumor Sites

12:00 pm Testing Genetically Engineered Macrophages to Transform the Solid Tumor Microenvironment

  • Courtney Crane Principal Investigator, Seattle Children’s Hospital

Synopsis

• Outline pre-clinical genetically modified macrophage data and path to clinic
• Discuss additional payloads for future and combination approaches
• Considerations for mechanistic insight in clinical trials to inform future design

12:30 pm CAR Macrophages: Tailor-Made for Solid Tumor Immunotherapy

Synopsis

• Address current challenges in solid tumor cellular therapy
• Overview of the Carisma CAR Macrophage platform
• Review the promise of CAR Macrophages in solid tumors

Depleting Immunosuppressive Macrophage Cells to Enhance Antitumor Immunity

1:00 pm Depleting Tumor-associated Macrophages to Create an Immune Stimulatory Environment

Synopsis

• Identify which population of immunosuppressive cells should be targeted to deplete
• Outline the safety and toxicity potential of this type of strategy
• Review the clinical translation opportunity of this therapy in combination

1:30 pm Lunch & Networking

Future Drug Development Opportunities for Macrophage-directed Therapies

2:30 pm Engineering Next Generation Macrophage from iPSC

  • Robert Deans Chief Technology Officer, Bluerock Therapeutics

Synopsis

• Enable allogeneic practice by gene editing the immune locus
• Control macrophage polarity using synthetic biology and logic circuits
• Understand how iPSC manufacturing transforms treatment paradigms from a transplant model to biologics

3:00 pm Macrophages in Cardiovascular Health

Synopsis

• Discuss the biology of monocytes and macrophages that reside and accumulate in atherosclerotic lesions but also in the healthy and injured heart and brain
• Outline how cells and their subsets pursue distinct functions in steady state and disease, and their tenure may range between hours to months; some subsets are highly inflammatory, while others support tissue repair
• Review current concepts of cell supply by the hematopoietic system, lineage relationships and systems’ cross talk
• Evaluate imaging tools for studying monocytes, macrophages and their progenitors

3:30 pm Chair’s Closing Remarks

  • Kipp Weiskopf Clinical Fellow, Hematology & Oncology, Dana-Farber Cancer Institute